Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

UroGen Pharma (URGN) Leases (2019 - 2025)

UroGen Pharma (URGN) has disclosed Leases for 7 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases rose 34.79% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, up 34.79%, and an annual FY2025 reading of $3.1 million, up 34.79% over the prior year.
  • Leases was $3.1 million for Q4 2025 at UroGen Pharma, down from $3.1 million in the prior quarter.
  • Across five years, Leases topped out at $3.1 million in Q3 2025 and bottomed at $641000.0 in Q1 2025.
  • Average Leases over 5 years is $1.8 million, with a median of $1.7 million recorded in 2021.
  • The sharpest move saw Leases plummeted 65.63% in 2021, then surged 194.49% in 2025.
  • Year by year, Leases stood at $1.2 million in 2021, then soared by 107.8% to $2.5 million in 2022, then tumbled by 31.85% to $1.7 million in 2023, then surged by 36.74% to $2.3 million in 2024, then surged by 34.79% to $3.1 million in 2025.
  • Business Quant data shows Leases for URGN at $3.1 million in Q4 2025, $3.1 million in Q3 2025, and $1.2 million in Q2 2025.